TELLURIDE, Colo., Feb. 15, 2024 — Despite recent record-setting IP expenditures, US enterprises waste $1 trillion annually by failing to monetize their IP assets.

ScaleIP (formerly LicenseLead) today announces a $1.5 million pre-seed financing to accelerate its pioneering IP business intelligence solution. This investment was led by the Greater Colorado Venture Fund, with participation from Tunitas Venture, Comeback Capital, Community Access Fund, and Seed Round Capital. The capital will accelerate ScaleIP’s ability to help more IP teams monetize their under-valued patents.

“The IP landscape is cluttered with underutilized patents,” said CEO and Co-founder Mark Leonard. “A surge in IP filings and record-setting corporate IP expenditures has pushed enterprises into rapidly adopting new monetization strategies. By harnessing transaction data, ScaleIP helps IP teams save labor time, gain new revenue streams, and support patent decision making by identifying and engaging with the most likely IP partners.”

The company was born in response conventional patent analytics tools, which often fail to reveal viable commercial partnerships. By leveraging intelligence with proprietary IP transaction data, ScaleIP is helping enterprises, universities, labs, and hospitals identify high-intent target companies to monetize underutilized their patents.

“Data is the gold in this new AI revolution,” said Cory Finney of the Greater Colorado Venture Fund. “In any industry that is hindered by fragmented data, there is opportunity. ScaleIP is at the forefront of unlocking new opportunities in this overlooked industry.”

Over 130+ IP dealmakers are using ScaleIP for several reasons:

• Licensing patents
• Selling patents
• Deciding whether to keep or abandon a patent.
• Seeking collaborators or partnerships.
• Determining their patent’s market value.

To learn more or sign up for a demo of ScaleIP by visiting ScaleIP.com.

About ScaleIP

ScaleIP combines IP transaction data with intelligence to streamline finding the right companies and people to license, sell, or collaborate around any patent. Visit ScaleIP.com for more information. ScaleIP is hiring!

SOURCE ScaleIP

Over 18 industry leaders, including SE Ventures (Schneider Electric), Home Depot, Fifth Wall, Ferguson, Suffolk Technologies, and Starwood Capital, now back Higharc as more builders switch to its integrated cloud platform.

DURHAM, N.C., Feb. 15, 2024 — Higharc, the connected cloud platform for homebuilding operations, announced today a $53 million Series B funding round powered by over 18 industry leaders from construction, building products manufacturing, and distribution.

The new financing follows the company’s rapid growth and customer demand in 2023, as it has emerged as the next-generation cloud software leader in the $350 billion US homebuilding industry.

Spark Capital and Pillar VC led the round, with participation from SE Ventures (Schneider Electric’s Venture Arm), Fifth Wall, Starwood Capital, Standard Investments, Home Depot, Ferguson, Simpson Strong-Tie, Mulhern+Kulp Engineering, Suffolk Technologies, RXR Realty, PSP Growth, Metaprop, SC Masterfund, Carl Bass — the former Autodesk CEO — along with leaders from Mighty Buildings, Welcome Homes, CBRE, and Ware Malcomb. ‘

The investment will be used to support Higharc’s growth and expand its automated materials estimating and generative AI-based workflows.

“Higharc exists to serve the hardworking teams who build homes across America–they’ve been stuck using 40-year-old software that wasn’t designed with their needs in mind, and they deserve better,” said Marc Minor, CEO of Higharc. “This additional capital reinforces Higharc’s long-term commitment to the success of our customers and to unlocking digital transformation for the entire homebuilding industry.”

Homebuilders Are Bringing New Communities to Market 3X Faster With Higharc
The adoption of Higharc’s generative design technology helped builders bring new homes and communities to market faster than ever in 2023, eliminating 90 days from the design cycle for new communities — a 75% reduction — while decreasing soft cycle time by 33%.

“Higharc is truly the ‘best in class’ way to draft new home designs and to guide potential buyers through the overwhelming personalization process prior to sale. We’re now more responsive than ever,” said Paul Hanson, President of Franchising at Epcon Communities and current Higharc customer.

Over one million homes are built annually in the U.S., yet we still have a housing shortage of five million homes¹. Builders often struggle to improve operational efficiency because they are stuck with old, siloed software solutions and inadequate data. The results are time-intensive manual processes, a “whack-a-mole” approach to changes, constant rework, and poor customer experiences.

Higharc’s Homebuilding Cloud replaces the “pen and paper” processes and software solutions that dominate the industry. Homebuilders get everything they need to design, estimate, sell and build homes in one place. This means departments can stay connected and in sync with accurate data while moving much faster. Whenever a plan changes, every department gets updated automatically with new 3D sales experiences, materials takeoffs, and construction documents — drastically reducing cycle time and costly rework.

“Higharc is modernizing a large, foundational industry that’s traditionally been tough to change with technology. By bringing together builders, manufacturers, and buyers, Higharc’s transformative technology is rewriting the rules of the design-to-construction process. This technology is fundamentally improving how we build homes in this country for generations to come,” said Alex Finkelstein, Co-founder and General Partner at Spark Capital.

Industry Insiders Invest to Accelerate Innovation in Homebuilding
The investment brings Higharc’s total capital raised since 2018 to $78.7 million, positioning the company to continue delivering on their mission to help build better and more affordable homes through technology.

Previous investors Javelin Venture Partners, Lux Capital, and Vertex Ventures also joined the round. Over 18 industry leaders came together to support Higharc’s growth and innovation in the industry.

“Higharc’s technology is second-to-none in the homebuilding space, offering a system that expedites the design-to-construction process and adds value to all stakeholders. In collaboration with Schneider Electric, SE Ventures is excited to help bring market insight and drive commercial deployment with homebuilders globally,” said Brad Jones, Principal at SE Ventures.

“I’ve rarely seen such a talented team come together around such a powerful shared vision,” said Russ Wilcox, Partner at Pillar VC. “They cracked the code on how software can help builders move from concept to construction with a smart and precise tool, which means owners get exactly what they want, and the job is both faster and cheaper. Everybody wins.”

To learn more about Higharc, visit higharc.com.

About Higharc
Founded in 2018, Higharc is the pioneer of The Homebuilding Cloud — the only connected platform that helps homebuilders transform how they design, sell, and build new homes and communities. Higharc customers today build over 40,000 homes annually representing $19 billion in new home sales volume. Headquartered in Durham, North Carolina, Higharc operates a remote-first workplace with over 70 full-time employees.

About Pillar VC
Pillar VC is an early-stage venture firm co-founded by 22 CEOs who have built Boston’s most successful companies, including the leaders of Wayfair, Ginkgo Bioworks, DraftKings, and Tripadvisor. Pillar is typically the first capital in for founders building next-generation pillar companies; the firm’s investments include PillPack, Desktop Metal, Jellyfish, JobGet, and Asimov, among other companies. To learn more, visit www.pillar.vc.

About Spark Capital
We are Spark Capital, investors in products we love by creators we admire, including Affirm, Anthropic, Cruise, Discord, Oculus, Plaid, Postmates, Slack, Twitter, and Wayfair. We know there are no playbooks or formulas for success and are here to help founders win their own way. We invest across all sectors and stages, and work out of San Francisco, Boston, and New York City.

¹Source: https://www.nar.realtor/june-is-national-homeownership-month/housing-supply-and-affordability

Contact Information:
Higharc
Cameron Austin
540-397-3554
[email protected]

SOURCE Higharc

NEW YORK, Feb. 14, 2024 — As we mark this milestone, we are filled with gratitude for the unwavering support of our clients and investors. Over the past decade your belief in our vision and commitment to excellence has been instrumental in propelling us forward.

Here’s to a decade of growth, partnership, and shared success.

Over this decade we continued to grow our investor distribution platform by consistently adding large Single Family Offices, Multi Family Offices, Private Credit Funds, Insurance Companies, Sovereigns, Endowments, and Private Equity funds to our investor platform. In addition to our initial direct Private Credit and direct Private Equity capital raise business, we have also added Fund Finance capabilities (raising NAV and Non-Dilutive GP Financings) as well as Commingled Private Credit, Private Equity, and select Hedge Fund LP Capital raises as well. Our investor distribution and product expansions reflect the capital needs of our clients in the ever-changing financial landscape.

“It is a great honor and privilege to have worked with such incredible clients and investors over these initial 10 years. The entire Cambridge Wilkinson team thanks you all, and we very much look forward to the next 10 years as we continue to grow and continue to offer additional capital raise services on our platform”, said Rob Bolandian, Co-founder and Global Head of Investment Banking at Cambridge Wilkinson.

www.cambridgewilkinson.com

About Us:
Cambridge Wilkinson is a leading global investment bank with the speed, connections, and the confidence to get transactions done. With a focus on middle-market companies, we arrange debt and equity capital raises from $25 million to $5 billion and advise on mergers and acquisitions. In addition, we also provide flexible and scalable leverage facilities and credit facilities for private equity funds and alternative credit funds which range from $25 million to $2 billion. We bring deep experience working with specialty finance institutions, real estate entities, funds as well as businesses spanning a variety of other industries. We offer unique access to a broad network of capital sources including large family offices, credit funds, banks, non-bank credit groups, insurance companies, private equity, sovereigns, and endowments.

All securities assignments are completed through Avalon Securities, Ltd. a FINRA member and SEC registered broker-dealer.

Rob Bolandian, Partner & Global Head of Investment Banking
[email protected]

Howard Chernin, Partner & COO
[email protected]

SOURCE Cambridge Wilkinson

LEHI, Utah, Feb. 15, 2024 — Consensus, the leader in Enterprise Demo Automation, announces the promotion of Whitney Jones to Chief Financial Officer.  In her previous role as VP of Finance and Business Operations, Whitney played a pivotal role in leading the financial strategy of Consensus, contributing significantly in securing the $110M Series C from Sumeru Equity Partners in February of 2023.

Whitney said, “I am beyond honored and excited to have been given the opportunity to be Chief Financial Officer at Consensus. We truly have something special here. I’m honored to work with this tremendously talented team. At Consensus, there is an authentic culture of innovation and desire to win the right way. There is endless potential for how Consensus will transform the enterprise buying experience.”

As the new CFO, Whitney will continue to play a pivotal role in steering Consensus towards new financial milestones, overseeing the financial and business operations, strategic planning, and fiscal responsibility of Consensus. This strategic move complements Consensus’s recent addition of Doug Johnson as CEO. It reflects Consensus’s commitment to fostering internal talent and maintaining a strong leadership team as the company continues to experience growth and success.

Doug, CEO at Consensus, said, “I am thrilled that Whitney has moved from Consensus’ VP of Finance and Business Operations to CFO. She has a proven track record of leading the organization’s financial and operational agenda. I have complete faith that Whitney will continue to help the company grow revenue and further our mission of using demo automation to make buying easier for the end customer.”

Consensus launched Tours in November 2023, which gives buyers a new way to explore products independently and asynchronously without forcing them to “click every click.” Presales, sales teams, and customer success can create a prescriptive story path that takes the buyer on a multipage immersive experience incorporating live product UI and task-based navigation. Demo pages will use both text and video explainers to demonstrate product features and value propositions. This frictionless approach enhances buyer product education and streamlines the sales process enabling Presales and Sales teams to compress buying cycles, reallocate internal time savings to high-value activities, and close more deals with fewer resources.

ABOUT CONSENSUS:

Consensus, the Intelligent Demo Automation Platform, scales presales instantly with interactive video demos. Presales and technical sales teams automate repetitive product demos which allows them to reallocate that time to higher value activities. Buyers get a better experience— one that guides them with digital, interactive and on-demand video demos. This uncovers stakeholders automatically and eliminates unqualified demos, which in turn dramatically shortens sales cycles by 29% up to 68% and improves close rates by up to 44%. Market leaders like Salesforce, SAP, Oracle, Autodesk, Sage, Trintech, Coupa and many others trust Consensus to scale. For more information, visit www.goconsensus.com or follow us on LinkedIn.

Media Contact:
Garrett Erickson
562-991-3702
[email protected] 

SOURCE Consensus

FreezeM aims to simplify BSF reproduction and increase protein yield through the supply of its PauseM® product to BSF protein producers, tapping an estimated $3.96 billion market by 2033 according to Meticulous Research forecast. This innovation plays a vital role in boosting insect protein production capacity for livestock and pet food while implementing a circular economy, conserving precious global farmland, and reducing ocean depletion.

Traditionally BSF breeding is a major bottleneck in industrial scale insect protein production, requiring unique bio-expertise to tackle inherent colony instabilities and technological gaps. While there are vast off-the-shelf engineering solutions for rearing and processing, breeding challenges can’t be addressed by machinery alone. As the insect farming industry matures, it follows a similar trajectory to other established agricultural market segments, moving towards supply chain specialization and segmentation. PauseM® is developed to overcome the fundamental challenges of insect breeding, thereby giving our customers’ competitive edge in the market. By eliminating these industry constraints, PauseM® not only promotes sector growth but also facilitates scaling of the global insect protein industry.

PauseM® is a ready-to-use product, containing life-cycle ‘paused’ BSF neonates with an extended shelf-life of 14 days and consistent high survival rates of over 90%. PauseM® is shipped to BSF protein facilities worldwide, stored on site and flexibly used according to production needs. This technology paves the way to a new decoupled BSF protein production model, separating the breeding phase from rearing and processing phases for the first time in the insect farming industry. The adoption of PauseM® as an outsourced ongoing breeding supply enables increased protein production efficiency, reduces Opex and Capex and streamlines seamless scalability.

FreezeM takes the breeding hurdle out of the equation, streamlining insect protein production and making it more efficient and accessible from new entrants to veteran market players. The newly established decoupled protein production model marks the first time the breeding phase is separated from the rearing and processing phases in the insect farming industry. The company currently supplies PauseM® globally, catering to small to large-scale BSF protein factories.

“The current funding round will enable FreezeM to embed our technology globally at scale and accelerate the growth of our breeding hubs in Europe and Israel, thereby driving successful commercial expansion. Our technology unleashes the insect market from its shackles and will propel the insect protein market to fulfill its true potential,” said Dr. Yuval Gilad, Co-founder and CEO of FreezeM.

About FreezeM

Founded in 2018 as a spin-off from the Weizmann Institute of Science by three institute graduates Yoav Politi, Idan Alyagor and Yuval Gilad. FreezeM’s mission is to make insect farming simple and accessible using novel breeding solutions for the emerging BSF farming industry. Since its establishment, the company has developed multiple biotechnological breakthroughs for enhancing sustainable, streamlined insect protein production. FreezeM was awarded several prestigious grants from the European Commission and the Israeli Innovation Authority, and participated in leading innovation consortiums in Europe and Israel.

Photo: https://mma.prnewswire.com/media/2338548/FreezeM.jpg

Media contact:
Peter Gorne
Head of Marketing
info@freeze-em.com 
+972502044934

–  Roche led the financing alongside existing and new investors – 

– The funds will progress clinical programs and expand platform capabilities –

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2024 — Freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and existing investors. The funding enables Freenome to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform.

Roche led the financing, joined by a16z Life Sciences Growth Fund, the American Cancer Society’s BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics (NYSE: DGX), RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, with funds and accounts advised by T. Rowe Price Associates, Inc., and others.

“We are grateful for the support and confidence of our investors. Together, we share a commitment to addressing the pressing need for better cancer screening solutions as we drive to make early cancer detection more convenient, accessible and actionable for everyone,” said Mike Nolan, chief executive officer of Freenome. “With this financing, we are well positioned to realize the full potential of our platform in delivering tests for early cancer detection.”

“We are excited by Freenome’s journey over the last few years, and we look forward to expanding our collaboration. Enabling wider access to early cancer screening means helping patients receive timely information that can lead to better outcomes. Freenome’s groundbreaking blood-based screening and data-driven insights offer incredible potential to transform personalized healthcare,” adds Matt Sause, chief executive officer of Roche Diagnostics.

Many lives are lost to cancer, in part because the disease is often detected late. Freenome is leveraging its multiomics platform, which uses computational biology, machine learning and other technologies to develop screening tools to detect cancer in its earliest, most treatable stages. The platform is also being evaluated alongside Freenome’s biopharma and diagnostic company partners to non-invasively detect minimal residual disease (MRD) augmented with biological insights derived from the multiomics platform.

“We look forward to collaborating with Freenome to advance the potential of their breakthrough multiomics technology for multi-cancer screening, building on our other initiatives to advance liquid biopsy innovations in cancer screening and minimal residual disease testing,” said Mark A. Gardner, senior vice president, molecular genomics and oncology, of Quest Diagnostics.

Freenome’s initial programs are focused on deadly and actionable cancers – colorectal and lung with a pipeline of single-cancer and multi-cancer tests under development. The company has two registrational studies underway:

• PREEMPT CRC: A >40,000-participant prospective clinical study with comprehensive longitudinal real-world data (RWD) evaluating Freenome’s blood-based screening test among adults at average risk for colorectal cancer (CRC).
• PROACT LUNG: A prospective observational clinical study enrolling up to 20,000 participants. The study is intended to validate Freenome’s lung screening test in current and former smokers 50 years and older who are eligible for screening with an LDCT scan.

Freenome is also developing tests to screen for other cancers as part of its multi-cancer research programs, including the Vallania Study and others. Combined, the multi-cancer studies will involve >10,000 participants with paired RWD.

• The Vallania Study: A multicenter, multi-cancer research program with more than 6,200 participants enrolled, including risk-matched control participants to reflect intended use populations. The study will compare blood samples from both cancer and non-cancer individuals to understand patterns associated with lung and other priority cancers.

About Freenome
Freenome is breaking barriers to early cancer detection with a suite of blood tests built on its multiomics platform. The company recognizes that no single technology can identify every cancer due to the inherent heterogeneity of the disease. Freenome’s multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer’s subtlest cues, even at the earliest stages of disease.

With the convenience of a standard blood draw, Freenome aims to empower everyone to access recommended cancer screenings. The company is partnering with healthcare organizations and population health decision-makers to integrate its technology and software platform, making cancer detection easier and more accessible. Freenome is headquartered in South San Francisco, California. Find out more at www.freenome.com and visit us on LinkedIn.

SOURCE Freenome Holdings, Inc.

SAN FRANCISCO, Feb. 14, 2024 — The American Academy of Orthopaedic Surgeons (AAOS) named CytexOrtho the winner of the inaugural OrthoPitch Technology Competition during the AAOS 2024 Annual Meeting in San Francisco. Through the competition, the AAOS, the world’s largest medical association of musculoskeletal specialists, aims to fuel innovation and foster advancements with the potential to improve or transform existing standards of orthopaedic care.

CytexOrtho, a pre-clinical stage medical device company working to advance orthopaedic treatment options for cartilage repair, presented a novel implant designed to naturally restore joints instead of artificially replacing them. The ReNew^™ Hip implant offers an innovative solution for the millions of active patients with early hip disease who are too young for a total hip replacement.

“The ReNew Hip implant is comprised of two very special components – one is a 3D-woven textile and the other is a high-precision, Tru3D printed component,” said Bradley Estes, PhD, founder and CEO of CytexOrtho, during the live pitch event. “The integration of these two components give us an implant that not only recreates the form and contour of a healthy articular joint surface but also recreates the function of articular cartilage and bone.”

According to Dr. Estes, surgeons remove only the damaged tissue and replace it with the implant. The implant restores the joint to its proper form and contour, and over time, cells move into the gaps in the layers of the implant and form functional tissue while the implant is slowly absorbed into the body. The technology received FDA Breakthrough Device designation and is poised to finish its phase 1 clinical trial and launch a phase 2 clinical trial once additional funding is secured.

“Being named winner of the first OrthoPitch competition validates the hard work our team at CytexOrtho has devoted to helping patients through this technology,” Dr. Estes said. “As we approach first-in-human clinical trials this year, we’re thrilled to receive this recognition from AAOS and are looking forward to promising outcomes.”

Presented by AAOS and sponsored by MCRA, OrthoPitch kicked off in July 2023 with a call for companies to submit a new technology or product concept with a focus on its impact on the practice of medicine and patient care. The AAOS Devices, Biologics and Technology (DBT) Committee conducted a multi-staged review process focused on ease to market, reimbursement coverage, impact on market and commercialization. The top four submissions—Biomedical Bonding AB, CytexOrtho, nView medical and Solenic Medical—were invited to pitch their concept live to a distinguished panel of regulatory, reimbursement and commercialization experts, physicians and investors during the AAOS Annual Meeting. Following the pitches, the audience was treated to a spirited round of questions from the panel of judges. Ultimately, CytexOrtho was named the winner, impressing both the judges and audience, which contributed to the outcome via a live online vote.

“Orthopaedic surgeons are at the forefront of new procedures and technologies to optimize patient care in an evidence-based approach,” said Jason L. Dragoo, MD, FAAOS, and DBT Committee chair. “With programs such as OrthoPitch, we’re able to nurture innovation(s) from the ground up and witness energy and excitement for the future of musculoskeletal care. The experience of being in person at the AAOS Annual Meeting gave new meaning to ‘pitching a deal’ and allowed each finalist the opportunity to receive valuable feedback.”

As grand prize winner, CytexOrtho will receive:

• Exposure to top seed and early-stage investors physicians, strategists and fellow industry members
• A complimentary booth at AAOS 2025 Annual Meeting in San Diego
• Complimentary regulatory or reimbursement assessment by a MCRA consultant
• One seat access to Axiom Health’s Market Intelligence Platform
• One 20-minute Innovation Theater time slot at the AAOS 2024 and 2025 Annual Meetings
• A complimentary webinar with AAOS
• One-on-one coordinated meetings with a minimum of nine leading MedTech investors

To learn more about the OrthoPitch terms and conditions, visit AAOS.org/OrthoPitch. For information about CytexOrtho, visit www.cytexortho.com.

About the AAOS
With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world’s largest medical association of musculoskeletal specialists. The AAOS is the trusted leader in advancing musculoskeletal health. It provides the highest quality, most comprehensive education to help orthopaedic surgeons and allied health professionals at every career level to best treat patients in their daily practices. The AAOS is the source for information on bone and joint conditions, treatments and related musculoskeletal health care issues; and it leads the health care discussion on advancing quality.

Follow the AAOS on Facebook, X, LinkedIn and Instagram.

About MCRA, LLC
MCRA is the leading privately held independent medical device, diagnostics and biologics Clinical Research Organization (CRO) and advisory firm. MCRA delivers to its client’s industry experience, integrating its six business value creators: regulatory, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics to provide a dynamic, market-leading effort from innovation conception to commercialization. MCRA’s integrated application of these key value-creating initiatives provides unparalleled value for its clients. MCRA has offices in Washington, DC, Hartford, CT, New York, NY, and Tokyo, Japan and serves nearly 1,000 clients globally. Its core focus areas of therapeutic experience include orthopedics, spine, biologics, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, anesthesia, general surgery, digital health, neurology, robotics, oncology, general and plastic surgery, urology, and in vitro diagnostic (IVD) devices and medical device cybersecurity. www.mcra.com.

SOURCE American Academy of Orthopaedic Surgeons

ORINDA, Calif., Feb. 14, 2024 — Wowzer AI is thrilled to announce its official launch, introducing a free, all-in-one platform designed to revolutionize content creation for both creative professionals and enthusiasts. Wowzer stands out as a comprehensive, user-friendly solution, providing access to top-tier AI models, cutting-edge model training, and prompt assistance, with more advanced features coming soon. By seamlessly merging industry-leading technologies, Wowzer empowers users to bring their creative visions to life with unparalleled speed and simplicity.

Wowzer’s multi-model image generator allows users to create images across various AI models simultaneously, including SDXL, Dall-E, Getty AI, and more, providing diverse styles and dynamic results with a single click. Designed with a focus on user-friendliness, Wowzer caters to both budding designers and seasoned professionals, making the creative journey rewarding and enjoyable for everyone.

In addition to providing access to the world’s most-used and most-secure AI image models with a single sign-on, the platform also offers a Prompt Enhancer to take the guesswork out of writing image prompts. The Prompt Enhancer suggests language based on prompt engineering principles, ensuring users get the exact image they want.

Additionally, Wowzer adopts a transparent and accessible pricing model, allowing users to dive into AI image generation with a free tier, called Wowzer Studio, and a pay-as-you-go membership for additional images and advanced features. Wowzer Studio includes the multi-model platform, Prompt Enhancer, and free credits every month. Users can also earn credits by sharing their generated images, participating in contests, and interacting with the Wowzer community of artists.

Upcoming features include additional AI models, images as input, upscaling, and advanced image controls, as well as plug-ins for easy integration with popular tools like Photoshop and Canva.

For enterprises, Wowzer offers GenAI Model Training, which brings the ability to create custom LLMs and image models with enterprise-grade security. GenAI Model Training is designed for businesses that want to uplevel their customer communications and brand consistency and empower a broader base of non-creatives so that any employee can become an on-brand contributor.

Peter Jackson, CEO of Wowzer AI, shared his excitement, saying, “What’s happening in AI right now is thrilling and full of possibilities, but it also can be confusing and scary at times. Our goal is to make AI image generation more accessible and less intimidating while capitalizing on the latest advances. We believe Wowzer is set to reshape the way generative AI is perceived and used.”

In preparation for launch, Wowzer partnered with Stability AI, the world’s leading open source generative AI company. “We’re thrilled to see Wowzer advancing the way businesses interact with Stability AI’s cutting-edge models,” said Scott Trowbridge, VP of Business Development at Stability AI. “Their prompt enhancer is a game-changer, simplifying the prompting process and enabling users to achieve remarkable outcomes without the need for extensive expertise in AI prompting. Wowzer AI’s contributions, powered by Stability AI, are crucial in democratizing the accessibility and utility of AI technology.”

For media inquiries or more information about Wowzer AI, please contact:

Renée Van Meekeren
VP of AI Marketing
Wowzer AI
Phone: 612-400-4452
Email: [email protected]
Website: www.wowzer.ai

About Wowzer AI

Wowzer AI is a free, all-in-one, AI-driven image generator and content workflow solution. With access to the industry’s best AI models, model training, and prompt assistance, creative professionals and amateurs alike are empowered to express their vision. Using Wowzer, creative concepts come to life with unprecedented speed and ease of use. Our passion is to inspire creativity and elevate human expression with approachable and tailored generative AI that protects the intellectual property of creators. Discover endless possibilities at Wowzer.ai and connect with us on Instagram, LinkedIn, and Facebook.

SOURCE Wowzer AI

CHICAGO, Feb. 14, 2024 — Architect Financial Technologies, Inc. (“Architect” or “the Company”), an emerging leader in derivatives brokerage services and trading technology, has closed a $12 million capital raise. With the completion of the new round, the Company has raised $17 million since its inception in January 2023. The round was co-led by BlockTower Capital and Tioga Capital, and attracted new investors including CMT Digital, ParaFi Capital, A Capital, and Twelve Below. These firms join a number of Architect’s founding investors – including Coinbase Ventures, SV Angel, Third Kind, SALT Fund, and US Digital Trust – in their continued participation.

Architect initiated the capital raise in response to significant developments in US derivatives and tokenized asset markets. The investment will support the imminent launch of Architect’s US derivatives brokerage for retail and institutional investors, offered through its CFTC-regulated subsidiary Architect Financial Derivatives LLC, and will facilitate the Company’s future expansion into US securities and security derivatives services. Additionally, the funding will enable the continued growth of Architect’s Chicago headquarters and further support its strategic expansion into EU and APAC jurisdictions.

Brett Harrison, founder and CEO of Architect, commented on the news: “As derivatives trading volume and open interest continues to surge across asset classes, and large financial institutions accelerate the primary issuance of tokenized assets, there is critical market demand for high-throughput, low-latency, trading and distribution infrastructure operated by regulated intermediaries with advanced technological capabilities. With the completion of this funding round and the support of our new and existing investors, Architect and its subsidiaries are well-positioned to assist a broader range of clients in navigating these market developments. We look forward to rapidly scaling our technology-forward, cross-asset brokerage services and institutional trading platforms.”

Architect provides institutions and professional investors with comprehensive trading and portfolio management software for traditional and digital asset markets across global jurisdictions. Its flagship platform offers algorithmic execution, advanced market visualization, discretionary trading, and risk management tools, supported by proprietary low-latency data normalization and exchange connectivity infrastructure. In September 2023, the Company’s subsidiary, Architect Financial Derivatives LLC, became an NFA-registered Independent Introducing Broker for CFTC-regulated derivatives. The Company recently launched Architect Edge, a cross-asset market data and event monitoring platform, and Architect Match, a portfolio management and trade reconciliation platform for financial institutions.

About Architect:

Architect Financial Technologies, Inc. is an institutional trading technology provider for global futures, options, and digital asset markets. Architect Financial Derivatives, LLC is an NFA-registered Independent Introducing Broker for CFTC-regulated derivatives.

To learn more, please visit https://architect.xyz.

This communication is for informational purposes only, and does not constitute a recommendation, investment, or legal advice. Readers should consult their investment, fiduciary, and/or legal advisors for guidance in making investment or business decisions.

SOURCE Architect Financial Technologies Inc